Public health authorities have relied on behavioral methods to ensure strict adherence to meet the world health organization`s goal of achieving viral suppression in 95% of patients on antiretroviral therapy (art).

Struggling to meet your deadline? Get your work done on time by experts. Don’t wait – ORDER NOW!

Meet my deadline

The purpose of this assignment is to draft and submit a complete, organized, detailed outline of your medication paper in APA format with sources cited and referenced accurately.
Medication Topic: While Highly Active Antiretroviral Therapy (HAART) has transformed the care and treatment of HIV, helping turn the tide against the epidemic at the turn of the 21st century, the effectiveness of the drugs depends on strict adherence to daily pill taking to achieve the treatment goal of viral suppression. Public health authorities have relied on behavioral methods to ensure strict adherence to meet the World Health Organization`s goal of achieving viral suppression in 95% of patients on antiretroviral therapy (ART). This goal is challenging in some patients, such as cognitively impaired and highly mobile individuals who require a flexible regimen to replace the daily pills. Cabenuva is the first long-acting injectable ART approved in January 2021 for patients 12 years and older and weighing at least 35kg virologically suppressed with previous regimens ("Fda Approves First," 2021).
Cabenuva consists of extended-release injections suspension of cabotegravir and rilpivirine. Both drugs already had established efficacy when used orally in ART regimens. The safety and efficacy of the injectable formulation were established in two clinical trials where virologically suppressed volunteers were switched to once-monthly injections, maintaining viral suppression with the new treatment ("Fda Approves First," 2021). Most side effects reported in the trials were minor and self-limiting, including injection site pain, fever, fatigue, headache, nausea, sleep disorders, dizziness, and rash ("Fda Approves First," 2021).
The drug dramatically enhances our capacity to eliminate the human immunodeficiency virus (HIV) by providing an opportunity to patients facing difficulties in achieving the high adherence required with oral drugs. Additionally, Cabenuva provides the first option for HIV patients unable to take or tolerate oral ART. Subsequent data have demonstrated effectiveness when administered as once every other month injection, further reducing injections from 12 to ten, a significant development for busy individuals who can schedule clinics seven days before or after the target treatment date (What Is Cabenuva, 2022). References
Fda approves first extended-release, injectable drug regimen for adults living with hiv. (2021, January 21). FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv
What is Cabenuva (cabotegravir; rilpivirine)? (2022). CABENUVA. https://www.cabenuva.com/about/what-is-cabenuva/
Adhere to the following guidelines for drafting and submitting your outline:
Use standard alphanumeric outline format.
Include a rough draft of your abstract.
Include APA in-text citations.
Include an APA formatted reference page.
Include a title page. Use APA format throughout.

Struggling to meet your deadline? Get your work done on time by experts. Don’t wait – ORDER NOW!

Meet my deadline